Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)

Active:	Yes
Cancer Type:		NCT ID:	NCT06132958
Trial Phases:	Phase III	Protocol IDs:	2870-005 (primary) NCI-2024-02180 2023-504816-14 jRCT2031240041 U1111-1288-7581
Eligibility:	18 Years and older, Female	Study Type:	Treatment
Study Sponsor:	Merck Sharp and Dohme LLC
NCI Full Details:	http://clinicaltrials.gov/show/NCT06132958

Summary

Researchers are looking for new ways to treat people with endometrial cancer (EC) who
have previously received treatment with platinum based therapy (a type of chemotherapy)
and immunotherapy. Immunotherapy is a treatment that helps the immune system fight
cancer. This clinical study will compare MK-2870 sacituzumab tirumotecan to chemotherapy.
The goal of the study is to learn if people who receive MK-2870 sacituzumab tirumotecan
live longer overall and without the cancer getting worse compared to people who receive
chemotherapy.

Treatment Sites in Georgia

Northside Hospital Cancer Institute
1000 Johnson Ferry Road NE
Atlanta, GA 30342
404-303-3355
www.northside.com

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.